Anaemia in elderly patients with cancer: Focus on chemotherapy-induced anaemia

Journal of Geriatric Oncology

Volumn 3, Issue 3, 2012, Pages 256-264

  Ludwig, H ^a   Wedding, U ^b   Van Belle, S ^c  

^a WILHELMINEN HOSPITAL   (Austria)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemotherapy induced anaemia (CIA); Elderly; Erythropoiesis stimulating agent (ESA); I.v. iron; Red blood cell (RBC) transfusion

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRON; LEVOLEUCOVORIN; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; RALTITREXED; RITUXIMAB;

AGED; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; COGNITION; COLORECTAL CANCER; COLORECTAL CARCINOMA; DOSAGE SCHEDULE COMPARISON; ERYTHROCYTE TRANSFUSION; FUNCTIONAL STATUS; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; IRON DEFICIENCY ANEMIA; LUNG NON SMALL CELL CANCER; MOOD; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 84862496018     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2012.02.006     Document Type: Review

References (74)

1. Papamichael D., Audisio R., Horiot J.C., Glimelius B., Sastre J., Mitry E., et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009, 20:5-16.
2. Surbone A., Kagawa-Singer M., Terret C., Baider L. The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Oncol 2007, 18:633-638.
3. Extermann M., Aapro M., Bernabei R., Cohen H.J., Droz J.P., Lichtman S., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005, 55:241-252.
4. Lewis J.H., Kilgore M.L., Goldman D.P., Trimble E.L., Kaplan R., Montello M.J., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003, 21:1383-1389.
5. Balducci L. Anemia, cancer, and aging. Cancer Control 2003, 10:478-486.
6. Ludwig H., Van B.S., Barrett-Lee P., Birgegard G., Bokemeyer C., Gascon P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40:2293-2306.
7. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., Klein H.G., Woodman R.C. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104:2263-2268.
8. Birgegard G., Aapro M.S., Bokemeyer C., Dicato M., Drings P., Hornedo J., et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005, 68(Suppl 1):3-11.
9. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999, 91:1616-1634.
10. Lucca U., Tettamanti M., Mosconi P., Apolone G., Gandini F., Nobili A., et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study. PLoS One 2008, 3:e1920.
11. Wedding U., Rohrig B., Pientka L., Hoffken K. Anaemia-related impairment in quality of life in elderly cancer patients prior to chemotherapy. J Cancer Res Clin Oncol 2007, 133:279-286.
12. Curt G.A. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000, 37:14-17.
13. Liao S., Ferrell B.A. Fatigue in an older population. J Am Geriatr Soc 2000, 48:426-430.
14. Penninx B.W., Cohen H.J., Woodman R.C. Anemia and cancer in older persons. J Support Oncol 2007, 5:107-113.
15. Dharmarajan T.S., Norkus E.P. Mild anemia and the risk of falls in older adults from nursing homes and the community. J Am Med Dir Assoc 2004, 5:395-400.
16. Luciani A., Jacobsen P.B., Extermann M., Foa P., Marussi D., Overcash J.A., et al. Fatigue and functional dependence in older cancer patients. Am J Clin Oncol 2008, 31:424-430.
17. Chaves P.H., Ashar B., Guralnik J.M., Fried L.P. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated?. J Am Geriatr Soc 2002, 50:1257-1264.
18. Balducci L. New paradigms for treating elderly patients with cancer: the comprehensive geriatric assessment and guidelines for supportive care. J Support Oncol 2003, 1:30-37.
19. Tchekmedyian N.S., Kallich J., McDermott A., Fayers P., Erder M.H. The relationship between psychologic distress and cancer-related fatigue. Cancer 2003, 98:198-203.
20. Mancuso A., Migliorino M., De S.S., Saponiero A., De M.F. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 2006, 17:146-150.
21. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003, 1:18-24.
22. Fried L.P., Bandeen-Roche K., Kasper J.D., Guralnik J.M. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol 1999, 52:27-37.
23. Overcash J. Symptom Management in the Geriatric Patient. Cancer Control 1998, 5:46-47.
24. Hardy D., Cormier J.N., Xing Y., Liu C.C., Xia R., Du X.L. Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer. J Thorac Oncol 2010, 5:90-98.
25. Chiara S., Lionetto R., Vincenti M., Bruzzone M., Nobile M.T., Gadducci A., et al. Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. Crit Rev Oncol Hematol 2001, 37:27-34.
26. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5:224-237.
27. Rizzo J.D., Brouwers M., Hurley P., Seidenfeld J., Arcasoy M.O., Spivak J.L., et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010, 28:4996-5010.
28. Smith R.E. The clinical and economic burden of anemia. Am J Manag Care 2010, 16:S59-S66. (Suppl Issues).
29. Repetto L. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit Rev Oncol Hematol 2009, 72:170-179.
30. Aapro M.S., Cella D., Zagari M. Age, anemia, and fatigue. Semin Oncol 2002, 29:55-59.
31. Tanvetyanon T., Choudhury A.M. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma. Cancer 2006, 106:1554-1559.
32. Cunningham R.S. Anemia in the oncology patient: cognitive function and cancer. Cancer Nurs 2003, 26:38S-42S.
33. Steurer M., Wagner H., Gastl G. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr 2004, 116:367-372.
34. Alter H.J., Klein H.G. The hazards of blood transfusion in historical perspective. Blood 2008, 112:2617-2626.
35. Koch C.G., Li L., Sessler D.I., Figueroa P., Hoeltge G.A., Mihaljevic T., et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008, 358:1229-1239.
36. Marik P.E., Corwin H.L. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008, 36:2667-2674.
37. Ludwig H., Fritz E. Anemia in cancer patients. Semin Oncol 1998, 25:2-6.
38. Popovsky M.A. Transfusion and lung injury. Transfus Clin Biol 2001, 8:272-277.
39. Francis D.M. Relationship between blood transfusion and tumour behaviour. Br J Surg 1991, 78:1420-1428.
40. Weng N.P. Aging of the immune system: how much can the adaptive immune system adapt?. Immunity 2006, 24:495-499.
41. Ford P.A., Mastoris J. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients. Transfusion 2004, 44:15S-25S.
42. Schiavetto I., Pedrazzoli P., Basilico V., Siena S. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia. Chemotherapy 2008, 54:417-420.
43. Auerbach M., Ballard H., Trout J.R., McIlwain M., Ackerman A., Bahrain H., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004, 22:1301-1307.
44. Vifor Pharma UK Limited Venofer (iron sucrose) summary of product characteristics Available from: URL:. http://www.medicines.org.uk/emc/medicine/24168/SPC.
45. Henry D.H., Dahl N.V., Auerbach M., Tchekmedyian S., Laufman L.R. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007, 12:231-242.
46. Rizzo J.D., Somerfield M.R., Hagerty K.L., Seidenfeld J., Bohlius J., Bennett C.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008, 111:25-41.
47. Steinmetz T., Tschechne B., Virgin G., Klement B., Felder M., Franzern M., et al. Ferric carboxymaltosefor the correction of cancer-and chemotherapy-induced anaemiain clinical practice. 16th Congress of EHA 2011, Ref Type: Abstract.
48. Dangsuwan P., Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010, 116:522-525.
49. Bastit L., Vandebroek A., Altintas S., Gaede B., Pinter T., Suto T.S., et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008, 26:1611-1618.
50. Steensma D.P., Sloan J.A., Dakhil S.R., Dalton R., Kahanic S.P., Prager D.J., et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011, 29:97-105.
51. Pedrazzoli P., Farris A., Del P.S., Del G.F., Ferrari D., Bianchessi C., et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008, 26:1619-1625.
52. Hedenus M., Birgegard G., Nasman P., Ahlberg L., Karlsson T., Lauri B., et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007, 21:627-632.
53. Auerbach M., Silberstein P.T., Webb R.T., Averyanova S., Ciuleanu T.E., Shao J., et al. Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010, 85:655-663.
54. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007, 43:258-270.
55. Aapro M.S., Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008, 13(Suppl 3):33-36.
56. Puglisi F., Deroma L., Russo S., Carteni G., Sporchia A., Ucci G., et al. Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients. Crit Rev Oncol Hematol 2009, 69:175-182.
57. Massa E., Madeddu C., Lusso M.R., Gramignano G., Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 2006, 57:175-182.
58. Amgen Aranesp Summary of Product Characteristics Available from: URL:. http://www.medicines.org.uk/emc/medicine/4981/.
59. Glaspy J., Crawford J., Vansteenkiste J., Henry D., Rao S., Bowers P., et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010, 102:301-315.
60. Ludwig H., Crawford J., Osterborg A., Vansteenkiste J., Henry D.H., Fleishman A., et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009, 27:2838-2847.
61. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-1542.
62. Repetto L., Carreca I., Maraninchi D., Aapro M., Calabresi P., Balducci L. Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol 2003, 45:123-128.
63. Locher C., Fabre-Guillevin E., Brunetti F., Auroux J., Delchier J.C., Piedbois P., et al. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit Rev Oncol Hematol 2008, 68:178-182.
64. Ramalingam S., Perry M.C., La Rocca R.V., Rinaldi D., Gable P.S., Tester W.J., et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 2008, 113:542-546.
65. Gridelli C., Kaukel E., Gregorc V., Migliorino M.R., Muller T.R., Manegold C., et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007, 2:221-229.
66. Tibaldi C., Bernardini I., Chella A., Russo F., Vasile E., Malventi M., et al. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006, 7:401-405.
67. Gebbia V., Verderame F., Ferrau F., Bordonaro R., Callari A., Caruso M., et al. Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. Ann Oncol 2006, 17(Suppl 7):vii60-vii65.
68. Okamoto I., Moriyama E., Fujii S., Kishi H., Nomura M., Goto E., et al. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2005, 35:188-194.
69. Tibaldi C., Ricci S., Russo F., Bernardini I., Galli L., Chioni A., et al. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO). Lung Cancer 2005, 48:121-127.
70. Sorraritchingchai S., Thongprasert S., Charoentum C., Chewasakulyong B., Moonprakan S. Treatment of advanced non-small cell lung cancer with vinorelbine in elderly Thai patients. J Med Assoc Thai 2004, 87:367-371.
71. Addeo R., Caraglia M., Costanzo R., Faiola V., Montella L., Abbruzzese A., et al. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients. Oncol Rep 2004, 12:135-140.
72. Maestu I., Gomez-Aldaravi L., Torregrosa M.D., Camps C., Llorca C., Bosch C., et al. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 2003, 42:345-354.
73. Gridelli C., Cigolari S., Gallo C., Manzione L., Ianniello G.P., Frontini L., et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001, 31:277-284.
74. Ricci S., Antonuzzo A., Galli L., Tibaldi C., Bertuccelli M., Lopes P.A., et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer 2000, 27:75-80.